(Q24658506)

English

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tsutomu Takeuchi

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Yoshiya Tanaka

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Manabu Iwasaki

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Hiroaki Ishikura

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Satoshi Saeki

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Yuichiro Kaneko

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

0 references

publication date

15 December 2015

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Annals of the Rheumatic Diseases

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

75

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1057-1064

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Janus kinases in immune cell signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

The Janus kinases (Jaks)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

Jak2 is essential for signaling through a variety of cytokine receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

The pathogenesis of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

Evolving concepts of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

7 April 2017

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

Intracellular signal pathways: potential for therapies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

New therapies for treatment of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

The Disease Activity Score and the EULAR response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 September 2017

A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

30 May 2018

Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 November 2018

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 November 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4893099

28 November 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic strategies for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Measurement of patient outcome in arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26672064

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1136/ANNRHEUMDIS-2015-208279

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

release_ylpsm5fe4zcttnnx3bi3u2vcdu

1 reference

https://api.fatcat.wiki/v0/release/ylpsm5fe4zcttnnx3bi3u2vcdu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26672064%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24658506&oldid=1874206516"